Home » The Journal Club Podcast
Hosted by SARC’s Chief Medical Officer, Dr. Scott Okuno, alongside a rotating guest host, SARC Talk: Journal Club explores the latest advances in sarcoma research through engaging discussions of recently published studies, emerging scientific discoveries, and their potential impact on patient care. Each episode features expert perspectives that help clinicians, researchers, patients, and advocates stay informed on the evolving landscape of sarcoma science.
In this episode of SARC Talk Journal Club, we review the recent Lancet Oncology phase II trial evaluating the combination of cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas. Our panel examines the study design, efficacy, safety profile, and clinical implications, discussing whether this combination represents a promising new treatment option and what questions remain for future research.
Spotify | YouTube | Apple Podcast
In this episode of SARC Talk Journal Club, our panel discusses the MANEUVER Phase III trial published in The Lancet, evaluating pimicotinib versus placebo in patients with tenosynovial giant cell tumor (TGCT). We review the study design, efficacy, safety profile, and patient-reported outcomes while exploring what these findings could mean for the treatment of unresectable, symptomatic TGCT.
In this episode of SARC Talk Journal Club, our panel discusses the EURO EWING 2012 Phase III trial, evaluating whether adding zoledronic acid to consolidation chemotherapy could improve outcomes for patients with Ewing sarcoma and Ewing-like sarcomas. The panel reviews the study design, key findings, event-free and overall survival outcomes, and the implications of adding zoledronic acid to treatment. What can this trial teach us about translating promising preclinical findings into clinical practice?